{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T15:55:19Z","timestamp":1795190119534,"version":"4.10.3"},"reference-count":47,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>Hyperhidrosis (chronic excessive sweating) may substantially affect an individual\u2019s emotional and social well-being. Therapies available before onabotulinumtoxinA were generally topical, with limited effectiveness, application-site skin reactions, and frequent, time-consuming treatments. Intradermal injection of onabotulinumtoxinA to treat sweat glands arose as a novel therapeutic approach. To develop this treatment, appropriate dosing needed to be established, and training on administration was required. Further, no previous scale existed to measure the effects of hyperhidrosis on patients\u2019 lives, leading Allergan to develop and validate the 4-point Hyperhidrosis Disease Severity Scale (HDSS), which measures the disease\u2019s impact on daily activities.<\/jats:p>\n          <jats:p>The onabotulinumtoxinA clinical development program for hyperhidrosis included 2 double-blind, placebo-controlled pivotal trials, immunogenicity studies, long-term studies of safety and efficacy, and quality of life assessments. In Europe and North America, the primary efficacy measures were, respectively, axillary sweat production measured gravimetrically and HDSS improvement. Compared with placebo, onabotulinumtoxinA treatment significantly reduced axillary sweat production and axillary hyperhidrosis severity, as measured by a 2-point or greater reduction on the HDSS. The effects of onabotulinumtoxinA occurred rapidly, within 1 week after injection, and lasted \u22656 months. Treatment with onabotulinumtoxinA was associated with significant quality of life improvements based on Short Form-12 physical and mental component scores. The Hyperhidrosis Impact Questionnaire also indicated greater treatment satisfaction, reduced negative impact on aspects of daily life, and improved emotional well-being with onabotulinumtoxinA versus placebo. The clinical development program and subsequent clinical experience showed that onabotulinumtoxinA treatment for hyperhidrosis was well tolerated with no new safety signals, and led to greater disease awareness.<\/jats:p>","DOI":"10.1097\/md.0000000000032764","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:01:52Z","timestamp":1690484512000},"page":"e32764","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Treatment of hyperhidrosis with Botox (onabotulinumtoxinA): Development, insights, and impact"],"prefix":"10.1097","volume":"102","author":[{"given":"Nicholas","family":"Lowe","sequence":"first","affiliation":[{"name":"Cranley Clinic, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Naumann","sequence":"additional","affiliation":[{"name":"University of Augsburg, Augsburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Eadie","sequence":"additional","affiliation":[{"name":"Former employee of Allergan plc, Irvine, CA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20240803","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1097\/01.pra.0000452570.69578.31","article-title":"The psychiatric facet of hyperhidrosis: demographics, disability, quality of life, and associated psychopathology.","volume":"20","author":"Lessa Lda","year":"2014","journal-title":"J Psychiatr Pract"},{"key":"R2-20240803","first-page":"16","article-title":"Correlation between dermatology life quality index and minor test and differences in their levels over time in patients with axillary hyperhidrosis treated with botulinum toxin type A.","volume":"19","author":"Skroza","year":"2011","journal-title":"Acta Dermatovenerol Croat"},{"key":"R3-20240803","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1365-2133.2004.06334.x","article-title":"Psychosocial aspects of patients with focal hyperhidrosis. Marked reduction of social phobia, anxiety and depression and increased quality of life after treatment with botulinum toxin A.","volume":"152","author":"Weber","year":"2005","journal-title":"Br J Dermatol"},{"key":"R4-20240803","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1046\/j.1468-1331.2001.00207.x","article-title":"Botulinum A toxin improves life quality in severe primary focal hyperhidrosis.","volume":"8","author":"Swartling","year":"2001","journal-title":"Eur J Neurol"},{"key":"R5-20240803","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1046\/j.1365-2133.2002.05059.x","article-title":"Effect of botulinum toxin type A on quality of life measures in patients with excessive axillary sweating: a randomized controlled trial.","volume":"147","author":"Naumann","year":"2002","journal-title":"Br J Dermatol"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.jaad.2010.03.013","article-title":"Clinical differentiation of primary from secondary hyperhidrosis.","volume":"64","author":"Walling","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"R7-20240803","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jaad.2003.12.029","article-title":"Recognition, diagnosis, and treatment of primary focal hyperhidrosis.","volume":"51","author":"Hornberger","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1610-0387.2007.06409.x","article-title":"Definition and treatment of primary hyperhidrosis.","volume":"5","author":"W\u00f6rle","year":"2007","journal-title":"J Dtsch Dermatol Ges"},{"key":"R9-20240803","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1159\/000446753","article-title":"Classification of systemic and localized sweating disorders.","volume":"51","author":"Ohshima","year":"2016","journal-title":"Curr Probl Dermatol"},{"key":"R10-20240803","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM200102153440704","article-title":"Botulinum toxin A for axillary hyperhidrosis (excessive sweating).","volume":"344","author":"Heckmann","year":"2001","journal-title":"N Engl J Med"},{"key":"R11-20240803","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s00403-016-1697-9","article-title":"Hyperhidrosis: an update on prevalence and severity in the United States.","volume":"308","author":"Doolittle","year":"2016","journal-title":"Arch Dermatol Res"},{"key":"R12-20240803","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.jaad.2018.12.071","article-title":"The etiology, diagnosis and management of hyperhidrosis: a comprehensive review. Part I. Etiology and clinical work-up.","volume":"81","author":"Nawrocki","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R13-20240803","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00403-019-01966-1","article-title":"Genetic disposition to primary hyperhidrosis: a review of literature.","volume":"311","author":"Henning","year":"2019","journal-title":"Arch Dermatol Res"},{"key":"R14-20240803","doi-asserted-by":"crossref","first-page":"e0244565e0244565","DOI":"10.1371\/journal.pone.0244565","article-title":"Genome-wide linkage analysis of families with primary hyperhidrosis.","volume":"15","author":"Schote","year":"2020","journal-title":"PLoS One"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1111\/bjd.13383","article-title":"A novel locus for primary focal hyperhidrosis mapped on chromosome 2q31.1.","volume":"172","author":"Chen","year":"2015","journal-title":"Br J Dermatol"},{"key":"R16-20240803","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10286-003-0082-x","article-title":"Primary hyperhidrosis\u2014evidence for autosomal dominant inheritance.","volume":"13","author":"Kaufmann","year":"2003","journal-title":"Clin Auton Res"},{"key":"R17-20240803","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1067\/mva.2002.119507","article-title":"Palmar hyperhidrosis: evidence of genetic transmission.","volume":"35","author":"Ro","year":"2002","journal-title":"J Vasc Surg"},{"key":"R18-20240803","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000346930","article-title":"Psychological sweating: a systematic review focused on aetiology and cutaneous response.","volume":"26","author":"Harker","year":"2013","journal-title":"Skin Pharmacol Physiol"},{"key":"R19-20240803","doi-asserted-by":"crossref","first-page":"e0272247","DOI":"10.1371\/journal.pone.0272247","article-title":"Real sweating in a virtual stress environment: investigation of the stress reactivity in people with primary focal hyperhidrosis.","volume":"17","author":"Schote","year":"2022","journal-title":"PLoS One"},{"key":"R20-20240803","first-page":"116","article-title":"Sweating disorders.","volume":"26","author":"Coon","year":"2020","journal-title":"Continuum (Minneap Minn)"},{"key":"R21-20240803","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0149-2918(03)90041-5","article-title":"Quality-of-life assessment in patients with hyperhidrosis before and after treatment with botulinum toxin: results of an open-label study.","volume":"25","author":"Campanati","year":"2003","journal-title":"Clin Ther"},{"key":"R22-20240803","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1046\/j.0007-1323.2001.02017.x","article-title":"Treatment of axillary hyperhidrosis.","volume":"89","author":"Naumann","year":"2002","journal-title":"Br J Surg"},{"key":"R23-20240803","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1007\/s11845-019-02131-3","article-title":"Five-year follow-up of patients treated with intra-dermal botulinum toxin for axillary hyperhidrosis.","volume":"189","author":"Lynch","year":"2020","journal-title":"Ir J Med Sci"},{"key":"R24-20240803","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jaad.2003.12.040","article-title":"US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey.","volume":"51","author":"Strutton","year":"2004","journal-title":"J Am Acad Dermatol"},{"key":"R25-20240803","first-page":"495","article-title":"Long-term efficacy and quality of life in the treatment of focal hyperhidrosis with botulinum toxin A.","volume":"28","author":"Tan","year":"2002","journal-title":"Dermatol Surg"},{"key":"R26-20240803","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"key":"R27-20240803","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jaad.2018.11.066","article-title":"The etiology, diagnosis and management of hyperhidrosis: a comprehensive review. Part II. Therapeutic options.","volume":"81","author":"Nawrocki","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"R28-20240803","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/14764172.2021.1957115","article-title":"A survey of long-term results with microwave energy device for treating axillary hyperhidrosis.","volume":"23","author":"Lin","year":"2021","journal-title":"J Cosmet Laser Ther"},{"key":"R29-20240803","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/ajd.12448","article-title":"A survey of patient satisfaction with use of microwave device for axillary hyperhidrosis.","volume":"58","author":"Scuderi","year":"2017","journal-title":"Australas J Dermatol"},{"key":"R30-20240803","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1524-4725.2011.02250.x","article-title":"A randomized, blinded clinical evaluation of a novel microwave device for treating axillary hyperhidrosis: the dermatologic reduction in underarm perspiration study.","volume":"38","author":"Glaser","year":"2012","journal-title":"Dermatol Surg"},{"key":"R31-20240803","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1524-4725.2012.02375.x","article-title":"Clinical evaluation of a microwave device for treating axillary hyperhidrosis.","volume":"38","author":"Hong","year":"2012","journal-title":"Dermatol Surg"},{"key":"R32-20240803","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jdcr.2020.03.006","article-title":"Development of inflammatory nodules and scarring mimicking hidradenitis suppurativa after treatment of axillary hyperhidrosis using a microwave-based energy device.","volume":"6","author":"Aleisa","year":"2020","journal-title":"JAAD Case Rep"},{"key":"R33-20240803","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1136\/bmj.323.7313.596","article-title":"Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial.","volume":"323","author":"Naumann","year":"2001","journal-title":"BMJ"},{"key":"R34-20240803","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1113\/jphysiol.1951.sp004551","article-title":"A further survey of the action of Clostridium botulinum toxin upon different types of autonomic nerve fibre.","volume":"113","author":"Ambache","year":"1951","journal-title":"J Physiol"},{"key":"R35-20240803","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.det.2014.06.013","article-title":"Botulinum toxin for axillary hyperhidrosis.","volume":"32","author":"de Almeida","year":"2014","journal-title":"Dermatol Clin"},{"key":"R36-20240803","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1111\/j.1365-2230.1996.tb00093.x","article-title":"Botulinum toxin\u2014a possible new treatment for axillary hyperhidrosis.","volume":"21","author":"Bushara","year":"1996","journal-title":"Clin Exp Dermatol"},{"key":"R37-20240803","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1001\/archderm.134.3.301","article-title":"Focal hyperhidrosis: effective treatment with intracutaneous botulinum toxin.","volume":"134","author":"Naumann","year":"1998","journal-title":"Arch Dermatol"},{"key":"R38-20240803","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1111\/j.1524-4725.1998.tb04257.x","article-title":"Botulinum A neurotoxin for axillary hyperhidrosis. No sweat Botox.","volume":"24","author":"Glogau","year":"1998","journal-title":"Dermatol Surg"},{"issue":"2 Pt 1","key":"R39-20240803","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/S0190-9622(98)70242-7","article-title":"Botulinum toxin therapy for palmar hyperhidrosis.","volume":"38","author":"Shelley","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"R40-20240803","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1007\/BF01652699","article-title":"Ein neues verfahren zu der klinischen untersuchung der schwei\u00dfabsonderung.","volume":"101","author":"Minor","year":"1928","journal-title":"Dtsch Z Nervenheilkd"},{"key":"R41-20240803","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/00000658-194608000-00007","article-title":"Indications and results of surgery of the autonomic nervous system in Naval personnel.","volume":"124","author":"Goodman","year":"1946","journal-title":"Ann Surg"},{"key":"R42-20240803","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/S0007-1226(50)80004-8","article-title":"The regeneration of sympathetic activity in grafted skin as evidenced by sweating.","volume":"3","author":"McGregor","year":"1950","journal-title":"Br J Plast Surg"},{"key":"R44-20240803","first-page":"87","article-title":"Axillary hyperhidrosis. Local treatment with aluminium-chloride hexahydrate 25% in absolute ethanol with and without supplementary treatment with triethanolamine.","volume":"68","author":"Glent-Madsen","year":"1988","journal-title":"Acta Derm Venereol"},{"key":"R45-20240803","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/BF00371820","article-title":"Baseline water loss and cholinergic sweat stimulation in atopic dermatitis: a gravimetric measurement of local skin water loss.","volume":"283","author":"Parkkinen","year":"1991","journal-title":"Arch Dermatol Res"},{"key":"R46-20240803","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.jaad.2007.01.009","article-title":"Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety.","volume":"56","author":"Lowe","year":"2007","journal-title":"J Am Acad Dermatol"},{"key":"R48-20240803","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1097\/DSS.0000000000001612","article-title":"Phase 3 study of onabotulinumtoxinA distributed between frontalis, glabellar complex, and lateral canthal areas for treatment of upper facial lines.","volume":"44","author":"De Boulle","year":"2018","journal-title":"Dermatol Surg"},{"issue":"2 suppl 2","key":"R49-20240803","first-page":"AB61","article-title":"Four-year longitudinal data on the efficacy and safety of repeated botulinum toxin type A therapy for primary axillary hyperhidrosis [abstract].","volume":"56","author":"Glaser","year":"2007","journal-title":"J Am Acad Dermatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032764","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:56:44Z","timestamp":1722736604000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032764"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":47,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032764","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}